REPLIGEN CORP

Key metrics

Financial performance

Over the last 9 fiscal years REPLIGEN CORP's revenue grew from $104.54M to $738.26M, a compound annual growth rate of 24.3%. Net profit margin compressed from 11.2% to 6.6% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,331 filings)

Recent press releases

• Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance2026-04-22

  _First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic_

• Repligen to Report First Quarter 2026 Financial Results2026-04-22

  The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of the Company’s website.

• Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network2026-04-17

  The Breda RTIC is Repligen’s third global training and innovation center, joining existing locations in Waltham, Massachusetts and Tokyo, Japan. The Breda opening event, held on April 15th, welcomed key biopharma and CDMO customers and highlighted Repligen’s continued investment in customer proximity and global support capabilities.

• Repligen Corporation to Present at Upcoming March Conferences2026-03-05

  A live webcast of the Leerink and KeyBanc presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the events.

• Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance2026-02-24

  _Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter_

Similar companies

The largest companies sharing REPLIGEN CORP's SEC industry classification (biological products, (no diagnostic substances)).